Related Experiment Videos
Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory
Peter G Steinherz1, Paul A Meyers, Laurel J Steinherz
1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. steinhep@MSKCC.ORG
Abstract:
Current treatments for relapsed/refractory leukemias are unable to achieve extended remissions in most patients even with multiagent chemotherapy. Clofarabine is a new nucleoside analog that has demonstrated clinical benefit in phase I-II studies, and is currently being studied in children and adults with leukemias and has been approved for the treatment of children with relapsed or refractory acute lymphocytic leukemia. We report the experience of three adolescents, two with acute lymphocytic leukemia in 3rd relapse and one with relapsed/refractory acute myeloid leukemia, who achieved complete remission with clofarabine. The remissions were sustained with repeated cycles of monotherapy for 47, 59, and 64 weeks, respectively.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics in Pediatric Patients: Drug Excretion